Visiogen Inc.'s Synchrony accommodating intraocular lens has dual optics, meaning that the ciliary muscles don't have to move it as much as other IOLs. The result, the company claims, is more accommodative power that translates into better vision at all distances. Like all IOL makers, Visiogen's point-of-entry will be cataract surgery, but it is eyeing the large presbyopia market.
4 Jenner Street, Suite 180
Irvine, CA 92618
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.